



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Miglustat hydrochloride

Cat. No.:	HY-17020A
CAS No.:	210110-90-0
Molecular Formula:	C ₁₀ H ₂₂ ClNO ₄
Molecular Weight:	255.74
Target:	Glucosylceramide Synthase (GCS)
Pathway:	Neuronal Signaling
Storage:	-20°C, stored under nitrogen
	* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 65 mg/mL (254.16 mM; Need ultrasonic)
H₂O : ≥ 34 mg/mL (132.95 mM)
* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.9102 mL	19.5511 mL	39.1022 mL
	5 mM		0.7820 mL	3.9102 mL	7.8204 mL
	10 mM		0.3910 mL	1.9551 mL	3.9102 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
Solubility: 100 mg/mL (391.02 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 3.25 mg/mL (12.71 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 3.25 mg/mL (12.71 mM); Clear solution
4. Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 3.25 mg/mL (12.71 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Miglustat (N-Butyldeoxynojirimycin) hydrochloride is an orally active and reversible ceramide glucosyltransferase inhibitor. Miglustat hydrochloride can be used for the research of type I gaucher disease^{[1][2]}.

In Vitro

Miglustat (200 μM; 2, 4 and 24 h) hydrochloride restores F508del-CFTR (cystic fibrosis transmembrane conductance regulator) function in cystic fibrosis (CF) bronchial epithelial IB3-1 and CuFi-1 cells. Miglustat hydrochloride reduces the

	inflammatory response to <i>P. aeruginosa</i> in both CF and non-CF bronchial cells^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
In Vivo	Miglustat (0.2 mg/kg; oral administration; once) hydrochloride is able to rescue synaptic plasticity deficits, to restore ERKs activation and to counteract hyperexcitability^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	NPC1 ^{-/-} mice ^[1]
	Dosage:	0.2 mg/kg
	Administration:	Oral administration; once
	Result:	Was able to rescue synaptic plasticity deficits, to restore ERKs activation and to counteract hyperexcitability.

CUSTOMER VALIDATION

- Cell. 2019 Dec 12;179(7):1483-1498.e22.
- Cell Rep. 2022 Jul 5;40(1):111049.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Maria Cristina Dechecchi, et al. Anti-inflammatory effect of miglustat in bronchial epithelial cells. *J Cyst Fibros*. 2008 Nov;7(6):555-65.
- [2]. G D'Arcangelo, et al. Miglustat Reverts the Impairment of Synaptic Plasticity in a Mouse Model of NPC Disease. *Neural Plast*. 2016;2016:3830424.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA